{"id":"NCT03901105","sponsor":"Avid Radiopharmaceuticals","briefTitle":"Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease","officialTitle":"Evaluation of the Relationship Between Baseline Flortaucipir PET Signal and Cognitive Change in Subjects With Early Alzheimer's Disease Participating in the I8D-MC-AZES Protocol Addendum D5010C00009 (2.1) (Tau Imaging)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-28","primaryCompletion":"2019-04-28","completion":"2019-04-28","firstPosted":"2019-04-03","resultsPosted":"2020-08-28","lastUpdate":"2020-08-28"},"enrollment":205,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Alzheimer Disease"],"interventions":[{"type":"DRUG","name":"flortaucipir F18","otherNames":["18F-AV-1451","[F-18]T807","LY3191748"]},{"type":"PROCEDURE","name":"Brain PET Scan","otherNames":[]}],"arms":[{"label":"Flortaucipir PET Scan","type":"EXPERIMENTAL"}],"summary":"This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).","primaryOutcome":{"measure":"Risk Ratio for AD Symptom Progression on CDR-SB","timeFrame":"Within 18 months of scan","effectByArm":[{"arm":"CMD (CDR-SB Change >=1)","deltaMin":119,"sd":null},{"arm":"No CMD","deltaMin":43,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0313"}]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33587110"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}